\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesThe ERA4Health Partnership has announced its first webinar, which will feature Calum MacRae, M.D., PhD, Vice Chair for Scientific Innovation in the Department of Medicine at Brigham & Women’s Hospital and a Professor of Medicine at Harvard Medical School. Dr. MacRae will share his expertise on creating health systems that foster continuous learning innovation and translation.
More information and registartion on the ERA4Health website. This webinar is funded by the European Union under the Horizon Europe Framework Programme.
Background information: The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) for Health and Well-being. This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European public health needs.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
